Evidence map›Paper›PMID 32787808›Full record

ArticleBMC nephrology2020

A girl with MIRAGE syndrome who developed steroid-resistant nephrotic syndrome: a case report.

Sho Ishiwa, Koichi Kamei, Kanako Tanase-Nakao, Shinsuke Shibata, Kunihiro Matsunami, Ichiro Takeuchi, Mai Sato, Kenji Ishikura, Satoshi Narumi

Open access · goldAbstract readCase Reports
In one paragraph

Article in BMC nephrology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Observational
  7. Emerging phenotypes linked to variants inFrontiers in endocrinology · 2022
    Article
  8. Article
  9. Article
  10. Somatic mosaicism in inherited bone marrow failure syndromes.Best practice & research. Clinical haematology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Sho IshiwaDivision of Nephrology and Rheumatology, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo, 157-8535, Japan.
Koichi KameiDivision of Nephrology and Rheumatology, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo, 157-8535, Japan. kamei-k@ncchd.go.jp.ORCID 0000-0003-3528-6961
Kanako Tanase-NakaoDepartment of Molecular Endocrinology, National Research Institute for Child Health and Development, Tokyo, Japan.
Shinsuke ShibataElectron Microscope Laboratory, Keio University School of Medicine, Tokyo, Japan.
Kunihiro MatsunamiDepartment of Pediatrics, Gifu Prefectural General Medical Center, Gifu, Japan.
Ichiro TakeuchiCenter for Pediatric Inflammatory Bowel Disease, Division of Gastroenterology, National Center for Child Health and Development, Tokyo, Japan.
Mai SatoDivision of Nephrology and Rheumatology, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo, 157-8535, Japan.
Kenji IshikuraDivision of Nephrology and Rheumatology, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo, 157-8535, Japan.
Satoshi NarumiDepartment of Molecular Endocrinology, National Research Institute for Child Health and Development, Tokyo, Japan.
National Center For Child Health and Development · JPGifu Prefectural General Medical Center · JPKeio University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMIRAGE syndrome is a recently discovered rare genetic disease characterized by myelodysplasia (M), infection (I), growth restriction (R), adrenal hypoplasia (A), genital phenotypes (G), and enteropathy (E), caused by a gain-of-function mutation in the SAMD9 gene. We encountered a girl with molecularly-confirmed MIRAGE syndrome who developed steroid-resistant nephrotic syndrome. CASE PRESENTATION: She was born at 33 weeks gestational age with a birth weight of 1064 g. She showed growth failure, mild developmental delays, intractable enteropathy and recurrent pneumonia. She was diagnosed as MIRAGE syndrome by whole exome sequencing and a novel SAMD9 variant (c.4615 T > A, p.Leu1539Ile) was identified at age four. Biopsied skin fibroblast cells showed changes in the endosome system that are characteristic of MIRAGE syndrome, supporting the genetic diagnosis. Proteinuria was noted at age one, following nephrotic syndrome at age five. A renal biopsy showed focal segmental glomerulosclerosis (FSGS) with immune deposits. Steroid treatment was ineffective. Because we speculated that her nephrosis was a result of genetic FSGS, we decided not to introduce immunosuppressive agents and instead started enalapril to reduce proteinuria. Although her proteinuria persisted, her renal function was normal at age eight.

conclusionsThis is the first detailed report of a MIRAGE syndrome patient with nephrotic syndrome. Because patients with MIRAGE syndrome have structural abnormalities in the endosomal system, we speculate that dysfunction of endocytosis in podocytes might be a possible mechanism for proteinuria.

Indexed as

Angiotensin-Converting Enzyme InhibitorsEnalaprilEsophageal Motility DisordersExome SequencingFemaleGlomerulosclerosis, Focal SegmentalGlucocorticoidsGrowth DisordersHumansHypoadrenocorticism, FamilialImmunologic Deficiency SyndromesInfantInfectionsIntestinal DiseasesIntracellular Signaling Peptides and ProteinsMutationAngiotensin-Converting Enzyme InhibitorsEnalaprilGlucocorticoidsIntracellular Signaling Peptides and ProteinsSAMD9 protein, humanEndocytosisFocal segmental glomerulosclerosis (FSGS)MIRAGE syndromeSAMD9Steroid-resistant nephrotic syndrome (SRNS)

Identifiers

PMID32787808
PMCPMC7424677
OpenAlexW3048392994

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.